Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1635jxs

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Apr 08	"Ask CAS" for self-help around the clock
NEWS 3	Jun 03	New e-mail delivery for search results now available
NEWS 4	Aug 08	PHAPMAMarketLetter(PHAPMAML) - new on STN
NEWS 5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 7	Sep 03	JAPIO has been reloaded and enhanced
NEWS 8	Sep 16	Experimental properties added to the REGISTRY file
NEWS 9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 11	Oct 24	BEILSTEIN adds new search fields
NEWS 12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 13	Nov 18	DRUGLIT has been renamed APOLLIT
NEWS 14	Nov 25	More calculated properties added to REGISTRY
NEWS 15	Dec 04	CSA files on STN
NEWS 16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 17	Dec 17	TOXCENTER enhanced with additional content
NEWS 18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS 20	Feb 13	CANCERLIT is no longer being updated
NEWS 21	Feb 24	METADEX enhancements
NEWS 22	Feb 24	PCTGEN now available on STN
NEWS 23	Feb 24	TEMA now available on STN
NEWS 24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 25	Feb 26	PCTFULL now contains images
NEWS 26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 27	Mar 20	EVENTLINE will be removed from STN
NEWS 28	Mar 24	PATDPAFULL now available on STN
NEWS 29	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 30	Apr 11	Display formats in IFGENE enhanced
NEWS 31	Apr 14	MEDLINE Reload
NEWS 32	Apr 17	Polymer searching in REGISTRY enhanced
NEWS 33	Apr 21	Indexing from 1947 to 1956 being added to records in CA/CAPLUS
NEWS 34	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS 35	Apr 28	RDISCLOSURE now available on STN
NEWS 36	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS 37	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS 38	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 39	May 16	CHEMREACT will be removed from STN
NEWS 40	May 19	Simultaneous left and right truncation added to WSCA
NEWS 41	May 19	RAPRA enhanced with new search field, simultaneous left and right truncation

```
 NEWS EXPRESS  April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:52:44 ON 27 MAY 2003

=> FIL MEDLINE BIOSIS EMBASE CA SCISEARCH
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'MEDLINE' ENTERED AT 16:52:48 ON 27 MAY 2003

FILE 'BIOSIS' ENTERED AT 16:52:48 ON 27 MAY 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 16:52:48 ON 27 MAY 2003
COPYRIGHT (C) 2003 Elsevier Science B.V.  All rights reserved.

FILE 'CA' ENTERED AT 16:52:48 ON 27 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'SCISEARCH' ENTERED AT 16:52:48 ON 27 MAY 2003
COPYRIGHT 2003 THOMSON ISI

=> s (phospholipase (n) a2 (n) group (n) V) or (calcium (n) dependent (n)
phospholipase (n) a2) or pla2g5 or hvpla2 or hpla2-10
L1          222 (PHOSPHOLIPASE (N) A2 (N) GROUP (N) V) OR (CALCIUM (N) DEPENDENT
                (N) PHOSPHOLIPASE (N) A2) OR PLA2G5 OR HVPLA2 OR HPLA2-10

=> s antisense or (anti (n) sense) or (complem? (2n) (oligo? or nucle))
L2       113696 ANTISENSE OR (ANTI (N) SENSE) OR (COMPLEM? (2N) (OLIGO? OR NUCLE
                ))

=> s l2 and l1
L3             5 L2 AND L1

=> dup rem l3
PROCESSING COMPLETED FOR L3
L4             5 DUP REM L3 (0 DUPLICATES REMOVED)

=> d l4 1-5 ibib abs

L4   ANSWER 1 OF 5  BIOSIS  COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
```

ACCESSION NUMBER: 2002:219032 BIOSIS
DOCUMENT NUMBER: PREV200200219032
TITLE: Mammalian phospholipase A2 nucleotide sequences, low molecular weight amino acid sequences encoded thereby, **antisense** sequences and nucleotide sequences having internal ribosome binding sites.
AUTHOR(S): Tischfield, Jay A. (1); Seilhamer, Jeffrey J.
CORPORATE SOURCE: (1) 9982 Mill Run, Carmel, IN, 46032 USA
ASSIGNEE: Tischfield; Jay A., Piscataway, NJ, USA; Incyte Pharmaceuticals, Inc.
PATENT INFORMATION: US 6352849 March 05, 2002
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Mar. 5, 2002) Vol. 1256, No. 1, pp. No Pagination. http://www.uspto.gov/web/menu/patdata.html. e-file.
ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English
AB Novel mammalian phospholipase (PLA2) nucleotide sequences and low molecular weight (about 14 KD) amino acid sequences encoded thereby are disclosed. More particularly, a cloned human HPLA2 cDNA expressing **HPLA2 -10** and its cloned rat RPLA2 cDNA counterpart, expressing RPLA2 -10, which are characterized as PLA2 Type IV, are disclosed. A second type of PLA2 cDNA, characterized as PLA2 Type III and exemplified by a rat PLA2 cDNA encoding RPLA2 -8 and a partial human PLA2 nucleotide sequence encoding HPLA2 -8, is disclosed. Expression of the cDNAs encode the two new types of PLA2 enzymes which have phospholipase activity. The novel PLA2 s do not include disulfide bridges between cysteine amino acids 11 and 77 or elapid loops. However, the novel PLA2 s may include amino acid COOH-terminal extensions which can vary in length. Seventeen of the eighteen absolutely conserved amino acids in all active 14 KD PLA2 s are believed to be conserved in RPLA2 -8 and HPLA2 -8, whereas all eighteen are believed to be conserved in RPLA2 -10 and **HPLA2 -10**. Because the encoded sequences of RPLA2 -8 and HPLA2 -8 include only 16 cysteine amino acids, they have been designated as Type III. RPLA2 -10 and **HPLA2 -10** are designated as Type IV since their encoded sequences include only 12 cysteine amino acids.

L4 ANSWER 2 OF 5 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 2000:278419 BIOSIS
DOCUMENT NUMBER: PREV200000278419
TITLE: Mammalian phospholipase A2 nucleotide sequences low molecular weight amino acid sequences encoded thereby **antisense** sequences and nucleotide sequences having internal ribosome binding sites.
AUTHOR(S): Tischfield, Jay A. (1); Seilhamer, Jeffrey J.
CORPORATE SOURCE: (1) Los Altos Hills, CA USA
ASSIGNEE: Tischfield; J., J., USA; Incyte Pharmaceuticals, Inc., USA
PATENT INFORMATION: US 5972677 October 26, 1999
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Oct. 26, 1999) Vol. 1227, No. 4, pp. No pagination. e-file.
ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English
AB Novel mammalian phospholipase (PLA2) nucleotide sequences and low molecular weight (about 14KD) amino acid sequences encoded thereby are disclosed. More particularly, a cloned human HPLA2 cDNA expressing **HPLA2 -10** and its cloned rat RPLA2 cDNA counterpart, expressing RPLA2 -10, which are characterized as PLA2 Type IV, are disclosed. A second type of PLA2 cDNA, characterized as PLA2 Type III and

exemplified by a rat PLA2 cDNA encoding RPLA2 -8 and a partial human PLA2 nucleotide sequence encoding HPLA2 -8, is disclosed. Expression of the cDNAs encode the two new types of PLA2 enzymes which have phospholipase activity. The novel PLA2 s do not include disulfide bridges between cysteine amino acids 11 and 77 or elapid loops. However, the novel PLA2 s may include amino acid COOH-terminal extensions which can vary in length. Seventeen of the eighteen absolutely conserved amino acids in all active 14KD PLA2 s are believed to be conserved in RPLA2 -8 and HPLA2 -8, whereas all eighteen are believed to be conserved in RPLA2 -10 and **HPLA2 -10**. Because the encoded sequences of RPLA2 -8 and HPLA2 -8 include only 16 cysteine amino acids, they have been designated as Type III. RPLA2 -10 and **HPLA2 -10** are designated as Type IV since their encoded sequences include only 12 cysteine amino acids.

L4 ANSWER 3 OF 5 CA COPYRIGHT 2003 ACS
ACCESSION NUMBER: 131:298644 CA
TITLE: Group V phospholipase A2-dependent induction of cyclooxygenase-2 in macrophages
AUTHOR(S): Balsinde, Jesus; Shinohara, Hiroyuki; Lefkowitz, Lee J.; Johnson, Christina A.; Balboa, Maria A.; Dennis, Edward A.
CORPORATE SOURCE: Department of Chemistry and Biochemistry, University of California at San Diego, La Jolla, CA, 92093-0601, USA
SOURCE: Journal of Biological Chemistry (1999), 274(37), 25967-25970
CODEN: JBCHA3; ISSN: 0021-9258
PUBLISHER: American Society for Biochemistry and Molecular Biology
DOCUMENT TYPE: Journal
LANGUAGE: English
AB When exposed for prolonged periods of time (up to 20 h) to bacterial lipopolysaccharide (LPS) murine P388D1 macrophages exhibit a delayed prostaglandin biosynthetic response that is entirely mediated by cyclooxygenase-2 (COX-2). Both the constitutive Group IV cytosolic phospholipase A2 (cPLA2) and the inducible Group V secretory phospholipase A2 (sPLA2) are involved in the cyclooxygenase-2-dependent generation of prostaglandins in response to LPS. Using the selective sPLA2 inhibitor 3-(3-acetamide-1-benzyl-2-ethylindolyl-5-oxy)propane sulfonic acid (LY311727) and an **antisense** oligonucleotide specific for Group V sPLA2, the authors found that induction of COX-2 expression is strikingly dependent on Group V sPLA2, which was further confirmed by expts. in which exogenous Group V sPLA2 was added to the cells. Exogenous Group V sPLA2 was able to induce arachidonate mobilization on its own and to induce expression of the COX-2. None of these effects was obsd. if inactive Group V sPLA2 was utilized, implying that enzyme activity is crucial for these effects to take place. Therefore, not only delayed prostaglandin prodn. but also COX-2 gene induction are dependent on a catalytically active Group V sPLA2. COX-2 expression was also blunted by the Group IV cPLA2 inhibitor Me arachidonyl fluorophosphonate, which the authors have previously found to block Group V sPLA2 induction as well. Collectively, the results support a model whereby Group IV cPLA2 activation regulates the expression of Group V sPLA2, which in turn is responsible for delayed prostaglandin prodn. by regulating COX-2 expression.
REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 5 CA COPYRIGHT 2003 ACS
ACCESSION NUMBER: 127:79056 CA
TITLE: Analysis of the secretory phospholipase A2 that mediates prostaglandin production in mast cells
AUTHOR(S): Reddy, Srinivasa T.; Winstead, Michelle V.; Tischfield, Jay A.; Herschman, Harvey R.

CORPORATE SOURCE: Departments Biological Chemistry Molecular Medical Pharmacology and the Molecular Biology Institute, UCLA Center Health Sciences, Los Angeles, CA, 90095-1570, USA

SOURCE: Journal of Biological Chemistry (1997), 272(21), 13591-13596
CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Prostaglandin D2 (PGD2) synthesis in activated mast cells occurs in two phases, an early phase that is dependent on prostaglandin synthase 1 and a delayed phase that is dependent on activation-induced prostaglandin synthase 2 gene expression. Early phase PGD2 synthesis in activated mast cells also requires the activity of a secretory phospholipase A2 (PLA2). It has been thought that the secretory PLA2 expressed in mast cells is group IIa PLA2, encoded by the Pla2 g2a gene. However, activated bone marrow-derived mast cells prepd. from Pla2 g2a+/+ mice and mast cells prepd. from mice with a mutation in the Pla2 g2a gene both demonstrate early phase PGD2 synthesis. Moreover, mast cells from both murine strains secrete PLA2 activity following activation. Northern and reverse transcriptase/polymerase chain reaction analyses demonstrate that mast cells from Pla2 g2a+/+ and Pla2 g2a-/- mice do not express group IIa PLA2 message. Instead, Northern and reverse transcriptase/polymerase chain reaction analyses demonstrate that both Pla2 g2a+/+ and Pla2 g2a-/- mast cells express mRNA for group V PLA2, encoded by the Pla2gV gene. An **antisense** oligonucleotide directed against group V PLA2 is also able to inhibit both the early phase pf PGD2 prodn. and the secretion of PLA2 activity by activated mast cells. Our data suggest that (i) group IIa PLA2 does not play a significant role in murine mast cell prostaglandin synthesis, (ii) group V PLA2 mediates early mast cell PGD2 prodn. and transcellular PGE2 prodn. in murine mast cells, and (iii) much of the data, based on studies with chem. inhibitors and antibodies, suggesting that group IIa PLA2 is responsible for arachidonic acid mobilization needs to be reevaluated.

L4 ANSWER 5 OF 5 CA COPYRIGHT 2003 ACS

ACCESSION NUMBER: 122:308083 CA

TITLE: Mammalian low molecular weight phospholipase A2 nucleotide and amino acid sequences

INVENTOR(S): Tischfield, Jay A.; Seilhamer, Jeffrey J.

PATENT ASSIGNEE(S): Indiana University Foundation, USA; Incyte Pharmaceuticals, Inc.

SOURCE: PCT Int. Appl., 159 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9502328	A1	19950126	WO 1994-US7926	19940715
W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2167296	AA	19950126	CA 1994-2167296	19940715
CA 2167296	C	20020219		
AU 9473622	A1	19950213	AU 1994-73622	19940715
US 5972677	A	19991026	US 1997-888497	19970707

US 6352849 B1 20020305 US 1999-352230 19990728
PRIORITY APPLN. INFO.: US 1993-91941 A 19930715
US 1993-97354 A 19930726
WO 1994-US7926 W 19940715
US 1996-651405 B1 19960522
US 1997-888497 A3 19970707

AB Novel mammalian phospholipase (PLA2) nucleotide sequences and low mol. wt. (about 14 KD) amino acid sequences encoded thereby are disclosed. More particularly, a cloned human HPLA2 cDNA expressing **HPLA2-10** and its cloned rat RPLA2 cDNA counterpart, expressing RPLA2-10, which are characterized as PLA2 Type IV, are disclosed. A second type of PLA2 cDNA, characterized as PLA2 Type III and exemplified by a rat PLA2 cDNA encoding RPLA2-8 and a partial human PLA2 nucleotide sequence encoding HPLA2-8, is disclosed. Expression f the cDNAs encode the two new types of PLA2 enzymes which have phospholipase activity. The novel PLA2s do not include disulfide bridges between cysteine amino acids 11 and 77 or elapid loops. However, the novel PLA2s may include amino acid COOH-terminal extensions which can vary in length. Seventeen of the eighteen absolutely conserved amino acids in all active 14 KD PLA2s are believed to be conserved in RPLA2-8 and HPLA2-8, whereas all eighteen are believed to be conserved in RPLA2-10 and **HPLA2-10**. Because the encoded sequences of RPLA2-8 and HPLA2-8 include only 16 cysteine amino acids, they have been designated as Type III. RPLA2-10 and **HPLA2-10** are designated as Type IV since their encoded sequences include only 12 cysteine amino acids.

=> d his

(FILE 'HOME' ENTERED AT 16:52:44 ON 27 MAY 2003)

FILE 'MEDLINE, BIOSIS, EMBASE, CA, SCISEARCH' ENTERED AT 16:52:48 ON 27 MAY 2003
L1 222 S (PHOSPHOLIPASE (N) A2 (N) GROUP (N) V) OR (CALCIUM (N) DEPEND
L2 113696 S ANTISENSE OR (ANTI (N) SENSE) OR (COMPLEM? (2N) (OLIGO? OR NU
L3 5 S L2 AND L1
L4 5 DUP REM L3 (0 DUPLICATES REMOVED)

=>
=> s l1 and inhib?
L5 115 L1 AND INHIB?

=> s l5 and (pharm? or antibod?)
L6 45 L5 AND (PHARM? OR ANTIBOD?)

=> s l6 and (ribozym? or nucl? (n) acid (n) inhib?)
3 FILES SEARCHED...
L7 0 L6 AND (RIBOZYM? OR NUCL? (N) ACID (N) INHIB?)

=> s l5 and (ribozym? or nucl? (n) acid (n) inhib?)
3 FILES SEARCHED...
L9 0 L5 AND (RIBOZYM? OR NUCL? (N) ACID (N) INHIB?)

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	74.80	75.01

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.86	-1.86

STN INTERNATIONAL LOGOFF AT 17:04:42 ON 27 MAY 2003